-$0.60 Earnings Per Share Expected for Madrigal Pharmaceuticals (MDGL) This Quarter

Analysts forecast that Madrigal Pharmaceuticals (NASDAQ:MDGL) will announce earnings of ($0.60) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Madrigal Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.46). Madrigal Pharmaceuticals reported earnings per share of ($0.69) during the same quarter last year, which would suggest a positive year over year growth rate of 13%. The business is scheduled to report its next quarterly earnings results on Thursday, August 9th.

According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.15). For the next fiscal year, analysts forecast that the business will post earnings of ($3.59) per share, with EPS estimates ranging from ($4.24) to ($3.20). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.33.



A number of brokerages have issued reports on MDGL. ValuEngine downgraded Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. BidaskClub downgraded Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright upped their price objective on Madrigal Pharmaceuticals to $178.00 and gave the company a “buy” rating in a research report on Thursday, May 24th. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cowen reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, May 10th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Madrigal Pharmaceuticals has a consensus rating of “Buy” and an average price target of $163.00.

Several hedge funds and other institutional investors have recently modified their holdings of MDGL. Citadel Advisors LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $35,002,000. Jennison Associates LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $18,744,000. Perceptive Advisors LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $17,338,000. Victory Capital Management Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 303.9% in the fourth quarter. Victory Capital Management Inc. now owns 204,206 shares of the biopharmaceutical company’s stock worth $18,744,000 after buying an additional 153,650 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 52.4% in the first quarter. BlackRock Inc. now owns 319,093 shares of the biopharmaceutical company’s stock worth $37,268,000 after buying an additional 109,665 shares during the period. Hedge funds and other institutional investors own 45.56% of the company’s stock.

Shares of MDGL stock opened at $108.43 on Monday. Madrigal Pharmaceuticals has a 1 year low of $13.09 and a 1 year high of $154.75. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -42.69 and a beta of 1.37.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply